These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 35239088)
21. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539 [TBL] [Abstract][Full Text] [Related]
22. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease. Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454 [TBL] [Abstract][Full Text] [Related]
23. Head-to-head comparison of three different US-based quantitative parameters for hepatic steatosis assessment: a prospective study. Zhou Y; Nie M; Zhou H; Mao F; Zhao L; Ding J; Jing X Abdom Radiol (NY); 2024 Jul; 49(7):2262-2271. PubMed ID: 38740581 [TBL] [Abstract][Full Text] [Related]
24. Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. Hong YM; Yoon KT; Cho M; Chu CW; Rhu JH; Yang KH; Lee JW Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):805-810. PubMed ID: 28379854 [TBL] [Abstract][Full Text] [Related]
25. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354 [TBL] [Abstract][Full Text] [Related]
27. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method. Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028 [TBL] [Abstract][Full Text] [Related]
28. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Hepatorenal B-Mode Ratio and the "Controlled Attenuation Parameter" for the Detection and Grading of Steatosis. Moret A; Boursier J; Houssel Debry P; Riou J; Crouan A; Dubois M; Michalak Provost S; Aubé C; Paisant A Ultraschall Med; 2022 Oct; 43(5):479-487. PubMed ID: 32992377 [TBL] [Abstract][Full Text] [Related]
30. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099 [TBL] [Abstract][Full Text] [Related]
31. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779 [TBL] [Abstract][Full Text] [Related]
33. New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. Koizumi Y; Hirooka M; Tamaki N; Yada N; Nakashima O; Izumi N; Kudo M; Hiasa Y PLoS One; 2019; 14(8):e0221548. PubMed ID: 31454369 [TBL] [Abstract][Full Text] [Related]
34. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. Bae JS; Lee DH; Lee JY; Kim H; Yu SJ; Lee JH; Cho EJ; Lee YB; Han JK; Choi BI Eur Radiol; 2019 Dec; 29(12):6499-6507. PubMed ID: 31175413 [TBL] [Abstract][Full Text] [Related]
35. Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. Tada T; Kumada T; Toyoda H; Kobayashi N; Sone Y; Oguri T; Kamiyama N AJR Am J Roentgenol; 2019 Feb; 212(2):332-341. PubMed ID: 30476453 [TBL] [Abstract][Full Text] [Related]
36. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093 [TBL] [Abstract][Full Text] [Related]
37. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971 [TBL] [Abstract][Full Text] [Related]
38. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665 [TBL] [Abstract][Full Text] [Related]
39. Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy. Jia S; Zhao Y; Liu J; Guo X; Chen M; Zhou S; Zhou J Front Pediatr; 2021; 9():784221. PubMed ID: 35087774 [No Abstract] [Full Text] [Related]
40. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]